This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer | MicrobiomeTrials
← Back to trials NCT07638501
Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-06-15Est. Completion: 2028-06-15
Enrollment target: 123 participantsLocations Eastern Hepatobiliary Surgery Hospital, Shanghai, China Other microbiome trials you might be interested in EGFR Overexpression Locally Advanced Solid Tumor Metastatic Solid Tumor
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Ad…
Seoul, South Korea Est. completion Jun 2027
Previously Treated, Advanced Biliary Tract Cancers
This study aims to evaluate the safety and preliminary efficacy of anlotinib combined with cadonilimab and PULSAR in pre…
Chengdu, China Est. completion Jun 30, 2027